Global Precision Oncology Diagnostics Market Outlook to 2032

Executive Summary

Precision oncology diagnostics is migrating from one-time tumour profiling toward longitudinal liquid-biopsy-and-MRD monitoring. The integrated category, spanning NGS-based tumour profiling, comprehensive genomic profiling, companion diagnostics, liquid biopsy, MRD monitoring, hereditary cancer testing, IHC/FISH biomarkers, and multimodal data platforms, grows from US$24 billion in 2024 to US$65 billion by 2032 at 13% CAGR.

Three forces drive the trajectory. Named operators have reached commercial scale with operating leverage: Tempus AI completed its Nasdaq IPO June 2024 and reported 83% YoY revenue growth to US$1.3 billion in 2025; Natera reported US$2.3 billion (up 36%) with oncology test volumes up 52%; Guardant Health raised 2025 revenue guidance three times to US$965-970 million (up 31%). FDA companion diagnostic approvals expanded materially in 2024-25, including Illumina TruSight Oncology Comprehensive (August 2024, the first US FDA-approved distributable CGP IVD with pan-cancer claims), Caris MI Cancer Seek (November 2024), and Idylla CDx MSI Test (August 2025). And CMS coverage architecture under the LCD MolDX framework provides structured Medicare reimbursement, with Signatera's 2025 fee schedule revised to multi-tier indication-specific pricing.

Market Overview

The precision oncology diagnostics scope captures seven flow components: NGS-based tumour profiling, liquid biopsy (ctDNA), MRD monitoring (tumour-informed ctDNA), FDA-approved companion diagnostics, hereditary cancer testing (BRCA1/2, Lynch, multi-gene panels), IHC/FISH biomarker testing, and multimodal data platforms (Tempus AI, Caris molecular intelligence). We exclude precision oncology therapeutics (the much larger category, valued at more than US$95 billion, covering targeted therapies and cell-and-gene therapies for oncology, sized separately).

The category sits at the intersection of three forces. The broader healthcare-IT and AI-enabled diagnostic transition (covered in our AI in Drug Discovery outlook). The FDA Laboratory Developed Test (LDT) Rule (May 2024) which subjects laboratory-developed tests to FDA premarket review under a phased four-year implementation, materially raising regulatory barriers for non-FDA-cleared tests. And oncology drug pipeline expansion: the US FDA approved over 80 oncology drugs and biologics in 2024-25 across solid tumours and hematologic malignancies, with each newly approved targeted therapy expanding the addressable diagnostic-test market through CDx pairing.

Geopolitically, North America anchors 40% of category value via US-headquartered scaled operators. Europe holds 26% (Roche-Foundation Medicine, Qiagen). China at 9% includes BGI, Burning Rock, Genetron, structurally exposed to BIOSECURE-Act-driven decoupling.

Market Size and Growth Outlook

The 2024-28 phase moderates to 13-16% as the category matures and per-test cost compression partially offsets volume growth. Three things compound: NGS oncology subset growth at 14.7% CAGR; MRD adoption acceleration from CRC-led to broader solid-tumour and lymphoma indications; and FDA companion diagnostic approval acceleration creating volume tailwind. By 2032, longitudinal monitoring (MRD, serial liquid biopsy, and surveillance) captures approximately 28% of category value (up from 12% in 2024).

Market Segmentation

By Test Type

NGS CGP at 37% is the largest single segment. The fastest-growing segments through 2032 are MRD (8% to 16% at 22% CAGR) and multimodal data platforms (6% to 14% at 26% CAGR). Companion diagnostics hold approximately stable share as FDA approval pace and targeted-therapy pipeline expansion sustain volume parallel to category growth.

By Cancer Type

Lung cancer at 22% leads because NSCLC has the broadest validated targeted-therapy panel (EGFR, ALK, ROS1, KRAS G12C, MET, BRAF, RET, HER2 TKD) and highest CGP attach rate. The fastest-growing indications through 2032 are colorectal (MRD-led growth) and bladder and renal cell (muscle-invasive bladder MRD).

By Buyer Cohort

Academic medical centres lead at 34% and remain technology-and-protocol leaders through 2032. Pharma at 18% is the fastest-growing buyer cohort (~22% CAGR through 2030) as data licensing, trial enrollment, and CDx contracts compound; pharma-channel revenue at Tempus AI grew 43.2% in 2024 alone.

Trends and Developments

MRD adoption from CRC-led to broader indications

Natera Signatera Q1 2025 clinical volume grew 52% YoY, anchored by colorectal cancer and expanding into breast, bladder, lymphoma. Natera ASH 2024 presentations demonstrated broad utility across lymphoma subtypes. Guardant Reveal and Foundation Medicine MonitorDx provide MRD competition. CMS coverage under multiple LCDs (L38779, L38816, L38822, L38835) provides structured Medicare reimbursement; Signatera 2025 fee schedule revisions (US$3,500 / US$2,919 / US$3,920 indication-specific tiers) reflect maturing payment differentiation. MRD becomes a longitudinal monitoring standard-of-care across most curative-intent solid-tumour treatment by 2030.

Tempus AI multimodal data platform commercial pull

Tempus AI Data and Services revenue grew 43.2% in 2024 to US$241.6 million, with continued acceleration into 2025. Pharma sponsors increasingly procure integrated clinical, genomic, imaging, and outcomes data as part of trial-design and regulatory-submission infrastructure. Tempus's Diagnostics segment grew 111.5% YoY to US$955.4 million in 2025. The multimodal data and diagnostics combination compounds: diagnostics generate data substrate, data substrate generates pharma-licensing revenue, pharma-licensing funds further diagnostics scale.

FDA companion diagnostic approval acceleration

Illumina TruSight Oncology Comprehensive (August 2024), the first US FDA-approved distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims (NTRK gene fusions for VITRAKVI; RET fusions in NSCLC for Retevmo). Caris MI Cancer Seek (November 2024) added pan-cancer and five tumour-specific indications. Idylla CDx MSI Test (August 15, 2025) added MSI-H detection in CRC for OPDIVO/YERVOY. Oncomine Dx Target Test added HER2 TKD for zongertinib; therascreen KRAS RGQ PCR Kit added KRAS G12C in CRC. The cumulative effect is FDA-cleared diagnostic toolkit expanded approximately 60% over 2023-25, a direct read-through from the upstream AI-led drug-discovery pipeline, where AI-discovered targeted therapies pull companion diagnostics into clearance alongside drug approvals.

Other relevant developments include liquid biopsy migration from advanced-disease into early-detection (Guardant Shield, Exact ColoSense), Tempus AI June 2024 Nasdaq IPO setting commercial template, Caris Life Sciences IPO filing 2025, the FDA LDT Rule (May 2024) raising regulatory barriers for non-FDA-cleared tests, and CMS LCD MolDX framework maturation with indication-specific pricing.

Competitive Landscape

Roche-Foundation Medicine leads at 16% (FoundationOne CDx, FoundationOne Liquid CDx; Roche subsidiary since 2018). Top-7 (Roche, Natera, Exact, Tempus, Guardant, Caris, Myriad) collectively control 49% of category value. Concentration is expected to increase moderately through 2032 as scaled operators with FDA-cleared portfolios consolidate share against LDT-rule-impacted smaller players. Tempus AI is the fastest-growing scaled operator on multimodal data and diagnostics combination.

Key Policies and Regulatory Environment

FDA Laboratory Developed Test (LDT) Rule (May 2024)

The FDA LDT Rule (final May 2024) subjects laboratory-developed tests to FDA premarket review under a phased four-year implementation. Stage 1 (May 2025) compliance with adverse event reporting; Stage 2 (May 2026) registration and listing; Stage 3 (May 2027) quality system; Stage 4 (May 2028) premarket review. Materially raises regulatory barriers for non-FDA-cleared tests; favours scaled operators with FDA-clearance infrastructure.

CMS LCD MolDX framework

LCD MolDX provides structured Medicare coverage for molecular diagnostics. MRD coverage under L38779, L38816, L38822, L38835 with disease-specific extensions. CMS fee schedule revisions in 2025 introduced multi-tier indication-specific pricing for Signatera (US$3,500, US$2,919, US$3,920). The binding US payment-side variable; scaled operators with structured LCD coverage capture predictable revenue.

Other relevant frameworks include the FDA Companion Diagnostic Approval Framework, EU IVDR (in force May 26, 2022 with phased compliance through 2025-26), China NMPA framework, Japan PMDA companion diagnostic framework, and India CDSCO emerging precision oncology diagnostics approval pathway.

Future Outlook

The precision oncology diagnostics market in 2032 reaches approximately US$65 billion. The structural shift through 2032 is migration from one-time tumour-tissue genomic profiling toward longitudinal liquid-biopsy-and-MRD monitoring throughout the patient journey, and integrated multimodal data platforms.

The competitive landscape consolidates moderately. Top-7 operators collectively control 56% of category value by 2032 (up from 49% in 2024). The test-type mix shifts: MRD expands from 8% to 16% on Signatera-led scale; multimodal data platforms expand from 6% to 14% as Tempus AI and Caris scale pharma-data-licensing revenue.

The biggest risk is a CMS reimbursement-rate compression event, particularly on Signatera-class MRD pricing. If MRD per-test reimbursement compresses more than 25% between 2026 and 2030, the back-half forecast (2029-32) compresses by 15-20%. Secondary risk is FDA LDT Rule implementation delay or modification reducing the regulatory-barrier-driven consolidation thesis.